18 June 2013 - Healthcare company Perrigo Company (NYSE:PRGO) (TASE:PRGO) announced on Monday that it has completed its acquisition of an ophthalmic sterile ointment and solution product portfolio for an upfront cash payment of approximately USD93m.

The seller is Fera Pharmaceuticals LLC and its affiliates (Fera).

Additionally, the transaction includes potential contingent payments of approximately USD36m, certain of which relate to Perrigo securing additional product rights from Fera.

Perrigo Company's acquired portfolio includes nine prescription ANDA products, which generated more than USD30m in net revenues during calendar year 2012.

In conjunction, Perrigo expects to receive a tax benefit from the acquisition, the net present value of which is estimated to be approximately USD20m.